NBNilanjana Banerjee

Nilanjana Banerjee

*This is an algorithmically generated author record based on publicly available information.

Nilanjana Banerjee has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Translating next generation sequencing to practice: Opportunities and necessary steps

    by Sitharthan Kamalakaran, Vinay Varadan, Angel Janevski, Nilanjana Banerjee, David Tuck, W. Richard McCombie, Nevenka Dimitrova, Lyndsay N. Harris

    Next‐generation sequencing (NGS) approaches for measuring RNA and DNA benefit from greatly increased sensitivity, dynamic range and detection of novel transcripts. These technologies are rapidly becoming the standard for molecular assays and represent huge potential value to the practice of oncology. However, many challenges exist in the transition of these technologies from research application to clinical practice. This review discusses the value of NGS in detecting mutations, copy number changes and RNA quantification and their applications in oncology, the challenges for adoption and the relevant steps that are needed for translating this potential to routine practice.


  • Open Access

    Effective normalization for copy number variation detection from whole genome sequencing

    by Angel Janevski, Vinay Varadan, Sitharthan Kamalakaran, Nilanjana Banerjee, Nevenka Dimitrova

    Whole genome sequencing enables a high resolution view of the human genome and provides unique insights into genome structure at an unprecedented scale. There have been a number of tools to infer copy number variation in the genome. These tools, while validated, also include a number of parameters that are configurable to genome data being analyzed. These algorithms allow for normalization to account for individual and population-specific effects on individual genome CNV estimates but the impact of these changes on the estimated CNVs is not well characterized. We evaluate in detail the effect of normalization methodologies in two CNV algorithms FREEC and CNV-seq using whole genome sequencing data from 8 individuals spanning four populations.


  • DNA methylation patterns in luminal breast cancers differ from non‐luminal subtypes and can identify relapse risk independent of other clinical variables

    by Sitharthan Kamalakaran, Vinay Varadan, Hege E. Giercksky Russnes, Dan Levy, Jude Kendall, Angel Janevski, Michael Riggs, Nilanjana Banerjee, Marit Synnestvedt, Ellen Schlichting, et al.

    The diversity of breast cancers reflects variations in underlying biology and affects the clinical implications for patients. Gene expression studies have identified five major subtypes– Luminal A, Luminal B, basal‐like, ErbB2+ and Normal‐Like. We set out to determine the role of DNA methylation in subtypes by performing genome‐wide scans of CpG methylation in breast cancer samples with known expression‐based subtypes. Unsupervised hierarchical clustering using a set of most varying loci clustered the tumors into a Luminal A majority (82%) cluster, Basal‐like/ErbB2+ majority (86%) cluster and a non‐specific cluster with samples that were also inconclusive in their expression‐based subtype correlations. Contributing methylation loci were both gene associated loci (30%) and non‐gene associated (70%), suggesting subtype dependant genome‐wide alterations in the methylation landscape. The methylation patterns of significant differentially methylated genes in luminal A tumors are similar to those identified in CD24 + luminal epithelial cells and the patterns in basal‐like tumors similar to CD44 + breast progenitor cells. CpG islands in the HOXA cluster and other homeobox (IRX2, DLX2, NKX2‐2) genes were significantly more methylated in Luminal A tumors. A significant number of genes (2853, p < 0.05) exhibited expression–methylation correlation, implying possible functional effects of methylation on gene expression. Furthermore, analysis of these tumors by using follow‐up survival data identified differential methylation of islands proximal to genes involved in Cell Cycle and Proliferation (Ki‐67, UBE2C, KIF2C, HDAC4), angiogenesis (VEGF, BTG1, KLF5), cell fate commitment (SPRY1, OLIG2, LHX2 and LHX5) as having prognostic value independent of subtypes and other clinical factors.


  • Open Access

    PAPAyA: a platform for breast cancer biomarker signature discovery, evaluation and assessment

    by Angel Janevski, Sitharthan Kamalakaran, Nilanjana Banerjee, Vinay Varadan, Nevenka Dimitrova